|
|
Mechanism of EZH2-mediated ERK/HIF-1α signaling pathway in promoting peritoneal dialysis-associated peritoneal fibrosis
FU Bi-ling, XIE Ting-fei, XU Yun-peng, ZHANG Yan-zi, CHEN Ji-hong
2026, 25 (06):
508-513.
doi: 10.3969/j.issn.1671-4091.2026.06.013
Objective To investigate the role of enhancer of zeste homolog 2 (EZH2) through regulating the extracellular signal-regulated kinase (ERK)/hypoxia inducible factor-1α (HIF-1α) signaling pathway in the pathogenesis of peritoneal dialysis-associated peritoneal fibrosis. Methods Cell studies: human peritoneal mesothelial cells were divided into 3 groups, control group, TGF-β group, and TGF-β+siEZH2 (TGF-β+small interference RNA targeting EZH2) group. Animal studies: the mouse peritoneal fibrosis model was divided into 3 groups, control group, model group, and model+EZH2 knockdown group. The expressions of EZH2, ERK, HIF-1α, α-SMA (α-smooth muscle actin), MMP2 (matrix metallo proteinase 2), IL-6 (interleukin-6), and MCP-1 (monocyte chemoattractant protein-1) were detected by qPCR and western blot. Peritoneal tissues were stained by HE and Masson method. Results Cell studies: TGF-β induced the transformation of human peritoneal mesothelial cells to fibroblasts, which was attenuated by knockdown of EZH2. Compared with those in the control group, the TGF-β group showed the increase of mRNAs and proteins of EZH2 (t=4.473 and 22.39, P=0.001 and <0.001), HIF-1α (t=5.873 and 3.763, P=0.004 and 0.019), α-SMA (t=20.71 and 4.587, P<0.001 and =0.010), and MMP2 (t=47.500 and 3.994, P<0.001 and =0.016), as well as the increase of p-ERK (t=3.355, P=0.028); IL-6 and MCP-1 were also upregulated (P<0.05). Compared with those in the TGF-β group, the TGF-β+siEZH2 group exhibited the reduction of mRNAs and proteins of EZH2 (t=32.430 and 4.886, P<0.001 and=0.008), HIF-1α (t=6.732 and 0.019, P=0.003 and 0.001), α-SMA (t=25.760 and 2.809, P<0.001 and =0.048), and MMP2 (t=45.30 and 3.119, P<0.001 and =0.035), as well as the reduction of p-ERK (t=2.851, P=0.046); IL-6 and MCP-1 were also downregulated (P<0.05). No intergroup differences were observed in ERK mRNA (P>0.05). Animal studies: the model group exhibited thickening of peritoneal mesothelial layer, fibrosis and inflammatory infiltration, which were ameliorated in the model+EZH2 knockdown group. Compared with the control group, the model group showed the increase of mRNAs and proteins of EZH2 (t=12.340 and 93.560, P<0.001), HIF-1α (t=3.891 and 35.250, P=0.017 and <0.001), α-SMA (t=17.540 and 15.020, P<0.001), and MMP2 (t=47.330 and 61.120, P<0.001), as well as the increase of p-ERK (t=102.800, P<0.001). Compared with the model group, the model+EZH2 knockdown group exhibited the reduction of mRNAs and proteins of EZH2 (t=3.313 and 29.040, P=0.029 and <0.001), HIF-1α (t=3.928 and 38.520, P=0.017 and <0.001), α-SMA (t=6.617 and 5.570, P=0.002 and 0.005), and MMP2 (t=5.406 and 10.150, P=0.005 and <0.001), as well as the reduction of p-ERK (t=59.460, P<0.001). No intergroup differences were observed in ERK mRNA (P>0.05). Conclusion EZH2 promotes peritoneal fibrosis by activating the ERK/HIF-1α pathway to upregulate the expressions of HIF-1α, α-SMA, MMP2 and inflammatory factors. Knockdown of EZH2 inhibits this pathway and attenuates fibrosis. Targeting the EZH2/ERK/HIF-1α pathway may represent a novel therapeutic strategy.
Metrics
|